Medicus Pharma Ltd

Compare

145 Followers

MDCX Stock Chart & Stats

$2.49

-$0.29(-9.70%)

At close: Jan 08 4:00 PM EST

$2.49

-$0.29(-9.70%)

Day’s Range― - ―

52-Week Range$1.79 - $8.94

Previous CloseN/A

Volume5.92K

Average Volume (3M)387.67K

Market Cap

$49.94M

Enterprise Value$38.01M

Total Cash (Recent Filing)$9.67M

Total Debt (Recent Filing)$4.97M

Price to Earnings (P/E)―

Beta1.31

Next Earnings

Nov 21, 2025

EPS Estimate

-0.29

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.43

Shares Outstanding20,468,103

10 Day Avg. Volume407,062

30 Day Avg. Volume387,674

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.76

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-2.45

Forecast

1Y Price Target

$20.00

Price Target Upside703.21% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessThe interim data showed a complete response rate of over 60%, which is considered compelling compared to the typical response rates of 20%-30%.

Collaboration And PartnershipsMedicus announced a collaboration with the Gorlin Syndrome Alliance to advance an Expanded Access IND for its D-MNA patch in basal cell carcinoma, enabling patients to receive treatment under physician supervision while generating supportive real-world data.

Regulatory ProgressThe FDA confirmed that a relative bioavailability study could support a 505(b)(2) pathway, providing a clear regulatory path forward.

Bears Say

Market ConditionsThe slow erosion in the stock over the last few months is believed to stem from a lack of significant catalysts amid challenging biotech markets, particularly for microcaps.

Medicus Pharma Ltd News

Medicus Pharma announces strategic collaboration with Gorlin Syndrome Alliance

Medicus Pharma (MDCX) announces a strategic collaboration with the Gorlin Syndrome Alliance, GSA, to advance compassionate access to...

6d ago

MDCX

Medicus Pharma announces first patient treated in UAE SKNJCT-004 Phase 2 study

Medicus Pharma (MDCX) announced the enrollment of the first patient in United Arab Emirates SKNJCT-004 phase 2 clinical...

13d ago

MDCX

Medicus Pharma Ltd’s Strategic Collaboration and Promising Phase 2 Results Justify Buy Rating

Medicus Pharma Ltd, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy...

4d ago

MDCX

Medicus Pharma Collaborates with Gorlin Syndrome Alliance for SKINJECT™ Access

Medicus Pharma Ltd ( ($MDCX) ) has provided an announcement. Medicus Pharma Ltd. has announced a strategic collaboration...

5d ago

MDCX

Medicus Pharma Expands Global Clinical Trials for Skin Cancer Treatment

Medicus Pharma Ltd ( ($MDCX) ) has issued an announcement. Medicus Pharma Ltd. has announced the enrollment of...

13d ago

MDCX

Medicus Pharma Completes Share Sales to YA II PN

Medicus Pharma Ltd ( ($MDCX) ) has shared an announcement. Medicus Pharma Ltd. has completed several sales of...

17d ago

MDCX

Medicus Pharma to Showcase Innovations at Maxim Growth Summit 2025

The latest announcement is out from Medicus Pharma Ltd ( ($MDCX) ). Medicus Pharma Ltd. announced its participation...

21d ago

MDCX

Medicus Pharma Ltd. to Showcase Biotech Innovations at Dubai Summit

Medicus Pharma Ltd ( ($MDCX) ) has shared an announcement. Medicus Pharma Ltd. announced its participation in the...

27d ago

MDCX

Medicus Pharma Ltd’s Promising Prospects: Innovative BCC Treatment and Strong FDA Support Drive Buy Rating

In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Medicus Pharma Ltd,...

1M ago

MDCX

Medicus Pharma Advances Skinject Development with Positive FDA Feedback

An announcement from Medicus Pharma Ltd ( ($MDCX) ) is now available. Medicus Pharma Ltd. has received positive...

1M ago

MDCX

Medicus Pharma announces feedback from FDA Type C Meeting for Skinject

Medicus Pharma (MDCX) announced feedback from Type C meeting with United States Food and Drug Administration. The purpose...

1M ago

MDCX

Medicus Pharma price target raised to $20 from $12 at Brookline

Brookline raised the firm’s price target on Medicus Pharma (MDCX) to $20 from $12 and keeps a Buy...

1M ago

MDCX

Medicus Pharma to Present Key Developments at Brookline Capital Markets

An announcement from Medicus Pharma Ltd ( ($MDCX) ) is now available. Medicus Pharma Ltd. is set to...

1M ago

MDCX

Medicus Pharma Secures $8 Million Financing to Advance Teverelix Development

Medicus Pharma Ltd ( ($MDCX) ) has shared an announcement. Medicus Pharma Ltd. has secured an $8 million...

2M ago

MDCX

MDCX FAQ

What was Medicus Pharma Ltd’s price range in the past 12 months?

Medicus Pharma Ltd lowest stock price was $1.79 and its highest was $8.94 in the past 12 months.

What is Medicus Pharma Ltd’s market cap?

Medicus Pharma Ltd’s market cap is $49.94M.

When is Medicus Pharma Ltd’s upcoming earnings report date?

Medicus Pharma Ltd’s upcoming earnings report date is Nov 21, 2025 which is in 17 days.

How were Medicus Pharma Ltd’s earnings last quarter?

Medicus Pharma Ltd released its earnings results on Aug 12, 2025. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.25 by -$0.18.

Is Medicus Pharma Ltd overvalued?

According to Wall Street analysts Medicus Pharma Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Medicus Pharma Ltd pay dividends?

Medicus Pharma Ltd does not currently pay dividends.

What is Medicus Pharma Ltd’s EPS estimate?

Medicus Pharma Ltd’s EPS estimate is -0.29.

How many shares outstanding does Medicus Pharma Ltd have?

Medicus Pharma Ltd has 20,468,103 shares outstanding.

What happened to Medicus Pharma Ltd’s price movement after its last earnings report?

Medicus Pharma Ltd reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.25. Following the earnings report the stock price went up 13.706%.

Which hedge fund is a major shareholder of Medicus Pharma Ltd?

Currently, no hedge funds are holding shares in MDCX

Medicus Pharma Ltd Stock Smart Score

Underperform

Fundamentals

Return on Equity

-340.46%

Trailing 12-Months

Asset Growth

35.91%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Medicus Pharma Ltd

Medicus Pharma Ltd (MDCX) is a pharmaceutical company specializing in the research, development, and commercialization of innovative medicines and healthcare solutions. The company operates within the pharmaceutical and biotechnology sectors, focusing on a diverse range of therapeutic areas including oncology, cardiovascular diseases, and immunology. Medicus Pharma Ltd is committed to improving patient outcomes through advanced drug therapies and cutting-edge research.

Medicus Pharma Ltd (MDCX) Earnings & Revenues

Historic Earnings Reports

MDCX Stock 12 Month Forecast

Average Price Target

$20.00

▲(703.21% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","16":"$16","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6,11,16,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.24,3.6061538461538465,4.972307692307693,6.338461538461538,7.704615384615384,9.07076923076923,10.436923076923076,11.803076923076922,13.169230769230769,14.535384615384615,15.901538461538461,17.267692307692307,18.63384615384615,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.24,3.6061538461538465,4.972307692307693,6.338461538461538,7.704615384615384,9.07076923076923,10.436923076923076,11.803076923076922,13.169230769230769,14.535384615384615,15.901538461538461,17.267692307692307,18.63384615384615,{"y":20,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.24,3.6061538461538465,4.972307692307693,6.338461538461538,7.704615384615384,9.07076923076923,10.436923076923076,11.803076923076922,13.169230769230769,14.535384615384615,15.901538461538461,17.267692307692307,18.63384615384615,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.54,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.4,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.44,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.56,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.99,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.32,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >